Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
Retrieved on:
Monday, January 9, 2023
IND, PRAME, PIWIL1, NSCLC, ImmTAC, Circulating tumor DNA, HBV, Neoplasm, GI, RECIST, Immunotherapy, Autoimmunity, HIV, DNA, Pancreatic cancer, Infection, Conference, ESMO, Webcast, TCR, Patient, CD3, Single, Cancer, HLE, Endometrial cancer, HLA-A24, Pharmaceutical industry, Vaccine, Video game, Fine chemical, Q4, IMC, Immunocore, EU
In addition, the Company is enrolling patients into a Phase 2/3 trial to investigate the potential of tebentafusp in advanced cutaneous melanoma.
Key Points:
- In addition, the Company is enrolling patients into a Phase 2/3 trial to investigate the potential of tebentafusp in advanced cutaneous melanoma.
- The IMC-F106C-101 trial is adaptive and enables combinations with standards-of-care including checkpoint inhibitors, chemotherapy, and tebentafusp.
- The Company believes IMC-R117C is the first PIWIL1 targeted immunotherapy and plans to submit an IND in Q4 2023.
- The Company plans to report data from the Single Ascending Dose portion of the Phase 1 HIV trial in 2023.